CAS 1374639-75-4
:LEE011 Succinate
Description:
LEE011 Succinate, also known by its chemical name as a selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6, is a compound that has garnered attention in cancer research. It is primarily studied for its potential therapeutic effects in treating various malignancies, including breast cancer and other tumors characterized by dysregulated cell cycle progression. The succinate form indicates that it is a salt or ester derived from succinic acid, which may enhance its solubility and bioavailability. LEE011 functions by disrupting the phosphorylation of retinoblastoma protein, thereby inhibiting cell cycle progression from the G1 to the S phase, leading to reduced proliferation of cancer cells. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are crucial for determining its efficacy and safety profile in clinical settings. As with many investigational drugs, ongoing studies are essential to fully elucidate its mechanism of action, optimal dosing regimens, and potential side effects in patients.
- 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide Succinate
- Ribociclib Succinate
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 7 products.
Ribociclib succinate
CAS:Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).Formula:C27H36N8O5Purity:99.9%Color and Shape:SolidMolecular weight:552.63Butanedioic acid, compd. with 7-cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (1:1)
CAS:Formula:C27H36N8O5Purity:98%Color and Shape:SolidMolecular weight:552.62537-Cyclopentyl-N,N-Dimethyl-2-((5-(Piperazin-1-Yl)Pyridin-2-Yl)Amino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxamide Succinate
CAS:7-Cyclopentyl-N,N-Dimethyl-2-((5-(Piperazin-1-Yl)Pyridin-2-Yl)Amino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxamide SuccinatePurity:98%Molecular weight:552.63g/molLEE011 Succinate
CAS:Controlled Product<p>Applications LEE011 is an orally bioavailable and highly specific CDK4/6 (cyclin-dependent kinase 4/6) inhibitor. LEE011 in combination with LGX818 (a V600E BRAF specific inhibitor) or BYL719 (a PIK3CA specific inhibitor) leads to robust anti-tumor activity in melanoma and breast cancer tumor models.<br>References Kim, S., et al.: Mol. Cancer Ther., 12, PR02 (2013); Rader, J., et al.: Clin. Cancer Res., 19, 6173 (2013)<br></p>Formula:C23H30N8O·C4H6O4Color and Shape:NeatMolecular weight:552.63
![Butanedioic acid, compd. with 7-cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0013AM.jpg&w=3840&q=75)
![7-Cyclopentyl-N,N-Dimethyl-2-((5-(Piperazin-1-Yl)Pyridin-2-Yl)Amino)-7H-Pyrrolo[2,3-D]Pyrimidine-6…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F54%2Fthumb%2FOR1026677.jpg&w=3840&q=75)
